At APLUSA, we take immense pride in the impact our publications have on enhancing patient care and elevating the overall well-being of individuals. By sharing the results of our tireless work, we provide valuable insights that can truly make a difference. We are thrilled to contribute to the advancement of medical knowledge and to empower healthcare professionals with reliable information that leads to better outcomes. With a steadfast commitment to excellence, we continue to pave the way for a healthier and brighter future for all.
Available Publications based on APLUSA works
| Year |
Authors |
Citation |
Links |
Journal |
Therapeutic Area |
|
2023 |
Nicolas Blin, Christine Mai, Siegfried Ertl, Elodie Schneider, Marine Leberre, Melissa Yilmaz |
Impact of Ethnicity in Treatment Choice for Multiple Myeloma in the 3 First Lines of Therapy: Data from Observational Retrospective Real-World Study in the USA |
|
Blood (2023) 142 (Supplement 1): 7288 |
Multiple Myeloma |
|
2023 |
Nicolas Blin, Christine Mai, Siegfried Ertl, Elodie Schneider, Marine Leberre, Melissa Yilmaz |
Main Treatment Choices in the 2 First Lines of Therapy for Multiple Myeloma in Patients with High Risk Cytogenetics: Lesson from the Real World in the EU5 Countries and the USA |
|
Blood (2023) 142 (Supplement 1): 7294. |
Multiple Myeloma |
|
2023 |
Maï C, Blin N, Ertl S, Schneider E, Leberre M, Yilmaz M, Voute M |
Actual Use in Real World Setting of Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma in EU5 Countries and in the US |
Poster presented at ISPOR EU 2023
|
ISPOR EU 2023 Poster session HSD116, November 15th, 2023 |
Multiple Myeloma |
|
2023 |
Nicolas Blin, Siegfried Ertl, Elodie Schneider, Christine Maï |
Actual usage of current systemic treatments and influence of key drivers for multiple myeloma in the first 2 lines of therapy. Data from real-world study in EU5 countries.
|
EHA 2023 abstract and poster |
Multiple Myeloma |
|
|
2023 |
Silverberg J. I., Mohawk J A., Cirulli J., Nograles K., Punzalan J. C., Kelly K.M., Kim B. S., Guttman-Yassky E., Lebwohl M. |
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient Survey.
|
Dermatitis. Volume: 34 Issue 2: March 16, 2023 |
Atopic dermatitis |
|
| 2022 | O. Lidove, A. Masseau, D. Lacombe, B. Dussol, S. Bekri, F. Dupuis, Y. Fardini, A. Fouilhoux, E. Noel | Attentes et préférences des patients atteints de maladie de Fabry vis-à-vis de leur traitement, sur la base du Patient Needs Questionnaire (PNQ) : résultats intermédiaires de l’étude SATIS-Fab | Online article |
La Revue de Médecine Interne Volume 43, Supplement 1, June 2022, Page A75 |
Rare disease (Fabry) |
|
2022 |
Guffon, Nathalie; Genevaz, Delphine; Lacombe, Didier; Le Peillet Feuillet, Eliane; Bausson, Pascale; Noel, Esther; Maillot, François; Belmatoug, Nadia; Jaussaud, Roland |
Understanding the challenges, unmet needs, and expectations of mucopolysaccharidoses I, II and VI patients and their caregivers in France: a survey study
|
|
Rare disease | |
|
2022 |
K. Aouad, D. Wendling, M. Breban, S. Dadoun, C. Hudry, A. Moltó, E. Pertuiset, L. Gossec |
Exploring remission concept in axial spondyloarthritis through the perception of rheumatologists using vignettes and priority ratings
|
Rheumatology | ||
|
2022 |
Frenel, J., Guiu, S., Guéroult-Accolas, L., Zernik, N., Lefeuvre-Plesse, C. and Moley-Massol, I. |
Experience of patients with metastatic breast cancer in France: results of the 2021 RÉALITÉS survey and comparison with 2015 results
|
|
Oncologie 2022-1018 |
Oncology |
Read on
APLUSA | Who we are
APLUSA is one of the world’s leading independent market research companies dedicated specifically to healthcare.
Patients Charts by APLUSA
Real-World Data (RWD) collected using anonymized patient charts is often augmented with stated reasons that explain individual treatment decisions.
Augmented Insights by APLUSA
APLUSA’s longstanding expertise in market research through global, real-world data collection is enhanced by a growing range of augmented insights solutions.
LET'S TALK!
Interested in discovering results from previous waves of one of our syndicated studies, or getting on board for the next one?
Contact our team via the link below and we'll be delighted to send over more information about our services or to discuss a specific project you are working on.
